Shares of Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 184.50 ($2.29) and traded as low as GBX 146 ($1.81). Faron Pharmaceuticals Oy shares last traded at GBX 170 ($2.11), with a volume of 134,879 shares changing hands.
Faron Pharmaceuticals Oy Stock Performance
The company has a market capitalization of £169.48 million, a P/E ratio of -506.25 and a beta of 0.36. The company’s 50 day moving average is GBX 184.38 and its 200-day moving average is GBX 185.71. The company has a current ratio of 1.45, a quick ratio of 1.09 and a debt-to-equity ratio of 922.55.
Faron Pharmaceuticals Oy Company Profile
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
See Also
- Five stocks we like better than Faron Pharmaceuticals Oy
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
- How Can Investors Benefit From After-Hours Trading
- Why New Tariffs Could Boost These 3 Basic Materials Stocks
- What is the Nikkei 225 index?
- MarketBeat Week in Review – 02/03 – 02/07
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
